We have located links that may give you full text access.
Five-year Clinical Outcomes of Inferior Quadrant Trabectome Surgery for Open Angle Glaucoma.
Journal of Glaucoma 2023 March 14
PRCIS: This retrospective study of 264 eyes having inferior-quadrant trabectome surgery confirms its safety and relatively effectiveness. Most patients however still require IOP-lowering agents and a considerable proportion may need additional glaucoma surgery.
PURPOSE: To report outcomes from a large single-centre cohort of inferiorly-applied trabectome surgery.
PATIENTS METHODS: Retrospective review of patients undergoing trabectome surgery for chronic open angle glaucoma (COAG) at the University Eye Clinic Bonn, Germany, from 2012 to 2020.
RESULTS: Twohundred-sixty-four eyes of 206 patients with COAG were included. Mean review period was 45.43 (range 12-101) months. 105 eyes (39.8%) underwent standalone surgery, of which 74 were pseudophakic and 31 phakic. Mean preoperative IOP was 17.58 mmHg (range 12-50 mmHg). 105 eyes (39.8%) developed a 'failure event' according to pre-defined criteria at a mean interval of 14.8 months post-op. In absolute terms, 211 patients (79.9%) had a long-term IOP >14 mmHg at 7.6 months, 174 patients (65.9%) >16 mmHg at 10.6 months, 127 patients (48.1%) >18 mmHg at 10.9 months and 77 patients (29.2%) >21 mmHg at 11.1 months. Over a five-year period, overall mean IOP remained stable at 13 mmHg. The majority of patients were still on glaucoma drops (mean number reduced from 2.9 to 2.7 agents). Sub-group analyses showed that higher pre-operative IOP was a positive predictor for failure whereas combined surgery (with phaco) had better IOP outcomes (16.5 mmHg vs. 19.3 mmHg respectively). 41 patients (15.5%) developed minor complications: 22 had high postoperative IOP within 3 months, 11 developed a self-resorbing hyphema, 6 had fibrinous uveitis.
CONCLUSIONS: Trabectome surgery is a safe and relatively effective procedure for lowering IOP but most patients still need IOP-lowering agents and a considerable proportion may need additional glaucoma surgery within a relatively short time. Inferior quadrant treatment may result in inferior IOP outcomes when compared to nasal quadrant surgery.
PURPOSE: To report outcomes from a large single-centre cohort of inferiorly-applied trabectome surgery.
PATIENTS METHODS: Retrospective review of patients undergoing trabectome surgery for chronic open angle glaucoma (COAG) at the University Eye Clinic Bonn, Germany, from 2012 to 2020.
RESULTS: Twohundred-sixty-four eyes of 206 patients with COAG were included. Mean review period was 45.43 (range 12-101) months. 105 eyes (39.8%) underwent standalone surgery, of which 74 were pseudophakic and 31 phakic. Mean preoperative IOP was 17.58 mmHg (range 12-50 mmHg). 105 eyes (39.8%) developed a 'failure event' according to pre-defined criteria at a mean interval of 14.8 months post-op. In absolute terms, 211 patients (79.9%) had a long-term IOP >14 mmHg at 7.6 months, 174 patients (65.9%) >16 mmHg at 10.6 months, 127 patients (48.1%) >18 mmHg at 10.9 months and 77 patients (29.2%) >21 mmHg at 11.1 months. Over a five-year period, overall mean IOP remained stable at 13 mmHg. The majority of patients were still on glaucoma drops (mean number reduced from 2.9 to 2.7 agents). Sub-group analyses showed that higher pre-operative IOP was a positive predictor for failure whereas combined surgery (with phaco) had better IOP outcomes (16.5 mmHg vs. 19.3 mmHg respectively). 41 patients (15.5%) developed minor complications: 22 had high postoperative IOP within 3 months, 11 developed a self-resorbing hyphema, 6 had fibrinous uveitis.
CONCLUSIONS: Trabectome surgery is a safe and relatively effective procedure for lowering IOP but most patients still need IOP-lowering agents and a considerable proportion may need additional glaucoma surgery within a relatively short time. Inferior quadrant treatment may result in inferior IOP outcomes when compared to nasal quadrant surgery.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app